MENU

Why this fund manager thinks the market is underappreciating ResMed Inc (ASX:RMD)

ResMed Inc (ASX: RMD) shares are up 0.35% today after reporting its FY18 result.

Although Michael Wayne from Medallion Financial is neutral on ResMed, he thinks that the market is underappreciating ResMed in regards to the shift towards remote monitoring technology.

He noted in a Livewire article that the market for ResMed is both competitive and compelling. According to the US National Heart Blood and Lung Institutes, 12 million people suffer from sleep apnoea, but only four million people have been diagnosed.

However, competition is rising from the likes of Fisher & Paykel Healthcare Corp Ltd (ASX: FPH), which is putting the ResMed gross margin under pressure. Declining margins can be a big dampener on profit growth even if revenues are rising.

To counter this, Mr Wayne said that ResMed is a clear leader in the remote monitoring technology space. He said “ResMed now has more than 5 million cloud-connected patient devices helping to develop a Software as a Service (SaaS) business with an accretive recurring revenue stream.”

There are many benefits to come from this including improving the medical professional and patient relationship, accuracy of data collection, diagnosis in a less invasive way and improving the willingness of the patient to seek help.

As I mentioned above, Mr Wayne is neutral on ResMed and the result today was in line with expectations, with revenue growing by 13% and profit rising by 8%.

At 30x FY19’s estimated earnings I’m not sure it’s an obvious buy. If the gross margin continues to fall then that could be a worry for long-term profit growth.

Another healthcare stock that's well worth watching is this market favourite.

The ASX small cap up 285% with no sign of stopping...

One Australian company has developed a state of the art device that's revolutionizing hospitals all over the world. Even better, this device is so profitable that the company rakes in 90% margins. That's a lot of cash. So no wonder the stock's up 285% since 2008 - with no signs of stopping...

To discover the name and code, simply click the link below. You'll discover our expert's #1 medical technology pick... and you can decide for yourself whether to get invested today.

Click here to claim your free report.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.